Fractyl Health gains as experimental procedure helps maintain weight-loss in study
View all comments(0)
Shares of drug developer Fractyl Health GUTS.O rise 24.7% to $1.26 before the bell
Co says patients treated with its experimental lead product Revita preserved weight loss after GLP-1 drug discontinuation
Revita is an outpatient endoscopic procedure designed to modify dysfunction in the part of the small intestine through hydrothermal ablation in order to restore metabolic health
At 3 months, those treated with Revita lost an additional 2.5% total body weight after stopping Eli Lilly's LLY.N tirzepatide, the active ingredient in its blockbuster obesity drug Zepbound, while those who had a sham procedure regained 10%
Up to last close, stock down 51% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.